Latest news from ClinMet on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/research-by-clinmet-scientific-founder-and-colleagues-point-to-enzyme-that-restores-function-in-diabetic-kidney-disease/?sc=rsin /articles/research-by-clinmet-scientific-founder-and-colleagues-point-to-enzyme-that-restores-function-in-diabetic-kidney-disease/?sc=rsin Thu, 31 Oct 2013 08:00:00 EST ClinMet today announced that researchers from The University of California, San Diego School of Medicine and colleagues have published new findings that could fundamentally change understanding of how diabetes-related diseases develop and how they might be better treated. A prevailing theory suggests that mitochondrial function is overactive in diabetes and leads to complications such as kidney, eye, nerve and possibly cardiovascular disease. However, these new studies suggest that real-time production of superoxide - a marker of mitochondrial activity - is actually reduced, rather than elevated, in diabetic kidney disease and potentially other organs as well. Furthermore, stimulating mitochondrial production, function and superoxide levels led to improvement in diabetic kidney disease. ClinMet /articles/newly-published-research-by-clinmet-founder-and-uc-san-diego-team-demonstrates-value-of-urine-based-metabolomics-to-translational-medicine/?sc=rsin /articles/newly-published-research-by-clinmet-founder-and-uc-san-diego-team-demonstrates-value-of-urine-based-metabolomics-to-translational-medicine/?sc=rsin Fri, 11 Oct 2013 09:05:00 EST ClinMet today announced that researchers from The University of California, San Diego School of Medicine have published new metabolomics research that uncovers a novel, characteristic and highly consistent biochemical signature in urine associated with diabetic kidney disease. The findings, which form a foundation of ClinMet's proprietary Clinical Metabolomics platform, have implications for the identification of clinically useful biomarkers for kidney function and for sharpening drug development and clinical trials related to chronic kidney disease, as well as to diabetes, obesity and cardiovascular disease. ClinMet